Q2 2026 13F · SEC CIK 1609251
Krensavage Asset Management, LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $263.2M
- Reported positions
- 18
- Top holdings a year, 3 yrs
- +21.4%
- Assets under management
- $300.2M
Krensavage Asset Management, LLC is a hedge fund that reported 18 positions worth $263.2M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Enanta Pharmaceuticals Inc (ENTA, 15.9%), Jazz Pharmaceuticals PLC (JAZZ, 15.4%), United Therapeutics Corp Del (UTHR, 14.3%). A portfolio copying its top holdings returned 21.4% a year over the last 3 years, against 20.4% for the S&P 500.
Krensavage Asset Management, LLC holdings all 18 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ENTAEnanta Pharmaceuticals Inc | 15.9% | +0.0% | $41.8M |
| JAZZJazz Pharmaceuticals PLC | 15.4% | +0.0% | $40.4M |
| UTHRUnited Therapeutics Corp Del | 14.3% | -17.8% | $37.5M |
| BMRNBiomarin Pharmaceutical Inc | 11.4% | +0.0% | $30.0M |
| EXELExelixis Inc | 7.7% | -10.8% | $20.2M |
| ABTAbbott Laboratories | 6.9% | +3900.0% | $18.1M |
| SNYNFSanofi SA | 5.3% | +0.0% | $13.8M |
| SUPNSupernus Pharmaceuticals | 5.0% | +0.0% | $13.1M |
| RAREUltragenyx Pharmaceutical in | 5.0% | +0.0% | $13.1M |
| VNDAVanda Pharmaceuticals Inc | 2.7% | +0.0% | $7.2M |
| BNTXBiontech SE | 2.1% | +0.0% | $5.5M |
| GSKGsk PLC | 1.9% | +0.0% | $5.1M |
| BIIBBiogen Inc | 1.6% | +0.0% | $4.3M |
| REGNRegeneron Pharmaceuticals | 1.4% | +50.0% | $3.7M |
| EMBCEmbecta Corp | 1.4% | +54.4% | $3.7M |
| ARDXArdelyx Inc | 1.0% | +6.9% | $2.7M |
| INMDInmode Ltd | 0.7% | +0.0% | $1.8M |
| EOLSEvolus Inc | 0.4% | +0.0% | $1.1M |
What Krensavage Asset Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
- ABT Abbott Laboratories+3900.0% shares
- EMBC Embecta Corp+54.4% shares
- REGN Regeneron Pharmaceuticals+50.0% shares
- ARDX Ardelyx Inc+6.9% shares
Reduced
- UTHR United Therapeutics Corp Del-17.8% shares
- EXEL Exelixis Inc-10.8% shares
Sold out
- INDV Indivior Pharmaceuticals Incwas 4.0%
- ALKS Alkermes PLCwas 1.5%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +50.1% /yr
- S&P 500 +20.1%
- 3 years
- +21.4% /yr
- S&P 500 +20.4%
- 5 years
- +11.2% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $263.2M | 18 |
| Q1 2026 | $255.7M | 20 |
| Q4 2025 | $283.1M | 18 |
| Q3 2025 | $234.7M | 17 |
| Q2 2025 | $188.9M | 15 |
| Q1 2025 | $180.9M | 14 |
| Q4 2024 | $169.0M | 12 |
| Q3 2024 | $178.5M | 13 |
| Q2 2024 | $217.8M | 13 |
| Q1 2024 | $225.5M | 12 |
| Q4 2023 | $281.9M | 12 |
| Q3 2023 | $271.6M | 12 |
Questions about Krensavage Asset Management, LLC's portfolio
What stocks does Krensavage Asset Management, LLC own?
Krensavage Asset Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 18 positions worth $263.2M. The largest are Enanta Pharmaceuticals Inc (ENTA) at 15.9%, Jazz Pharmaceuticals PLC (JAZZ) at 15.4%, United Therapeutics Corp Del (UTHR) at 14.3%, Biomarin Pharmaceutical Inc (BMRN) at 11.4% and Exelixis Inc (EXEL) at 7.7%.
What did Krensavage Asset Management, LLC buy last quarter?
In Q2 2026, Krensavage Asset Management, LLC added Abbott Laboratories (ABT) (+3900.0% shares), Embecta Corp (EMBC) (+54.4% shares) and Regeneron Pharmaceuticals (REGN) (+50.0% shares), compared with its Q1 2026 filing.
What did Krensavage Asset Management, LLC sell last quarter?
In Q2 2026, Krensavage Asset Management, LLC sold all of Indivior Pharmaceuticals Inc (INDV), sold all of Alkermes PLC (ALKS), United Therapeutics Corp Del (UTHR) (-17.8% shares) and Exelixis Inc (EXEL) (-10.8% shares), compared with its Q1 2026 filing.
How has Krensavage Asset Management, LLC's portfolio performed?
A portfolio copying Krensavage Asset Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +21.4% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +50.1% against +20.1%. Over 5 years: +11.2% a year against +11.6%.
When is Krensavage Asset Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Krensavage Asset Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Krensavage Asset Management, LLC manage?
Krensavage Asset Management, LLC reported $300.2M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $263.2M.